Form 4: Indaptus Therapeutics Director Roger Pomerantz Granted 30,000 Stock Options

Indaptus Therapeutics, Inc. Director and 10% Owner Roger Pomerantz was granted 30,000 stock options with an exercise price of $0.33, vesting on June 10, 2026.

Summary

• Roger Pomerantz, a Director and 10% Owner of Indaptus Therapeutics, Inc. (INDP), acquired 30,000 derivative securities in the form of stock options.
• The transaction date for this acquisition was June 10, 2025.
• Each stock option has an exercise price of $0.33.
• The options will vest and become exercisable on June 10, 2026.
• The expiration date for these stock options is June 10, 2035.
• Following this transaction, Mr. Pomerantz directly beneficially owns 30,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, indicating confidence in future performance, though it's a routine compensation event.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options gain value if the company's stock price increases.
• The exercise price of $0.33 per share indicates a potential future upside for the options if the stock performs well.

Future Outlook

The stock options granted to Director Roger Pomerantz are set to vest on June 10, 2026, indicating a future milestone for the exercisability of these securities.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all industries, including the biotechnology and pharmaceutical sectors where Indaptus Therapeutics operates. Such grants are standard practice for executive and director compensation, aiming to incentivize long-term performance.

Related Party Transactions

• The grant of 30,000 stock options to Roger Pomerantz, a Director and 10% Owner of Indaptus Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can be viewed positively as it aligns the director's financial incentives with the long-term performance of the company's stock, potentially benefiting shareholders if the stock price increases.

Next Steps

• The stock options granted to Roger Pomerantz are scheduled to vest on June 10, 2026, at which point they will become exercisable.

Key Dates

Keywords

Indaptus Therapeutics, INDP, Stock Option, Director, Beneficial Ownership, Roger Pomerantz, SEC Form 4, Insider Transaction